Updated:
98point6 Technologies
98point6 Technologies licenses an AI-driven primary-care platform to health systems and payers, founded by Robbie Cape in Seattle.
98point6 Technologies
98point6 Technologies emerged from Seattle in 2015, co-founded by Robbie Cape, the former Microsoft executive who previously sold social-shopping startup Cozi to the tech giant. The company was built to deliver on-demand, text-based primary care via an AI-powered chatbot that automates clinical interviews before handing cases to board-certified physicians. Early venture rounds from L Catterton, Activant Capital, and Goldman Sachs Merchant Banking Division pushed the company to a post-money valuation near $435 million by 2018 (per PitchBook, 2018). The initial consumer brand, simply called 98point6, built a licensed medical group across all 50 states. Strategy shifted decisively in 2022 when 98point6 sold its physician-staffed medical group and consumer-facing app to Transcarent for approximately $100 million (per TechCrunch, 2022). The remaining entity, re-launched as 98point6 Technologies, licenses its core technology stack — combining natural language processing with an evidence-based clinical rule engine — directly to health systems, payers, and large employers that want to automate portions of primary-care triage and follow-up within their own branded experiences. The platform allows enterprise clients to embed an asynchronous AI clinician into their own apps, supporting millions of patients with clinical content reviewed by a centralized physician team. The company holds multiple patents on automated clinical interview technology. Post-pivot, 98point6 Technologies operates as a leaner SaaS-like business, though exact team size remains undisclosed. The company announced a $20 million Series A extension in early 2023, naming The Growth Fund of L Catterton as a returning investor (per 98point6 Technologies, January 2023). Offices remain in Seattle, Washington. The firm supports deployments across the United States and has cited early traction with regional health systems and self-insured employers looking to reduce per-visit primary-care costs through asynchronous AI. What separates 98point6 Technologies from most digital-health peers is the technology's original design for full episode-of-care management rather than simple symptom checking. The AI does not stop at triage; it drafts a complete encounter note that a physician reviews asynchronously, creating a hybrid workflow now licensed to organizations that control their own physician networks. The governance model puts the adoption decision and legal liability on the licensed enterprise, not on a distributed gig-network of third-party doctors — a structure built for scaled local deployment without rebuilding provider credentialing from scratch.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Seattle
Corporate office
Seattle, WA, United States
Principals
Robbie Cape
Co-founder and CEO
Sector focus
Frequently asked questions
Who runs investment decisions at 98point6 Technologies?
The company is venture-backed and operated by its co-founder and CEO Robbie Cape, who controls the strategic direction of the firm in conjunction with a board including investors from L Catterton and Activant Capital. Cape's background as a Microsoft executive and repeat founder shapes the product-led growth strategy.
How is 98point6 Technologies different from the original 98point6 telemedicine app?
In 2022, 98point6 sold its consumer-facing business and employed physician group to Transcarent for approximately $100 million (per TechCrunch, 2022). What remained — 98point6 Technologies — is a pure technology licensor that sells its AI-powered clinical software to health systems and payers, not directly to patients. The company no longer employs front-line clinicians.
Does 98point6 Technologies compete with Teladoc or Amwell?
Not directly. Teladoc and Amwell primarily sell telemedicine services that connect patients to their own employed or contracted physicians. 98point6 Technologies sells the underlying AI platform for asynchronous, automated primary-care interactions — a tool that health systems or payers then integrate into their own branded offerings and pair with their own doctors.
Is 98point6 Technologies structured as a venture-capital-backed startup or a corporate venture?
It is a venture-capital-backed private company. Key investors include The Growth Fund of L Catterton, Activant Capital, and Goldman Sachs Merchant Banking Division. The company has raised over $100 million across multiple rounds since its founding, including a $20 million extension in early 2023 (per the firm, January 2023).
What investment stage or deployment model does 98point6 Technologies use?
98point6 Technologies does not make external investments, hold a portfolio, or deploy capital as a fund. It is an operating technology company that builds and licenses enterprise software. All capital raised from institutional investors has gone into product development, engineering, and commercial deployment of its own platform.
Does 98point6 Technologies own any patents or proprietary clinical models?
Yes. The company holds multiple US patents covering automated clinical interview technology and the AI architecture that generates encounter notes from patient chat interactions. This intellectual property is the core asset offered through its enterprise licensing agreements.
Does 98point6 Technologies maintain any direct-to-consumer operations?
No. All direct-to-consumer services, including the original mobile app and the affiliated medical group, were transferred to Transcarent in the 2022 acquisition. The company now exclusively serves enterprise clients — health systems, payers, and large self-insured employers — offering a white-label platform for their own patient or member populations.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: